Shmuel Rubinstein - Clal Biotechnology External Director

CBI Stock   44.10  0.50  1.12%   

Director

Mr. Shmuel Rubinstein serves as External Director at Clal Biotechnology Industries Ltd. since February 17, 2011. He also serves Tero Pharma Industries Ltd. since 1990. since 2011.
Age 78
Tenure 13 years
Phone972 3 612 1616
Webhttps://www.cbi.co.il

Clal Biotechnology Management Efficiency

The company has return on total asset (ROA) of (0.1194) % which means that it has lost $0.1194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4545) %, meaning that it generated substantial loss on money invested by shareholders. Clal Biotechnology's management efficiency ratios could be used to measure how well Clal Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 52.28 M in total debt with debt to equity ratio (D/E) of 6.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clal Biotechnology has a current ratio of 3.6, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Clal Biotechnology until it has trouble settling it off, either with new capital or with free cash flow. So, Clal Biotechnology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Clal Biotechnology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Clal to invest in growth at high rates of return. When we think about Clal Biotechnology's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Gilead HalevyCompugen
51
David GranotBezeq Israeli Telecommunication
71
Doron TurgemanBezeq Israeli Telecommunication
49
Dov HershbergCompugen
74
Amikam ShorerBezeq Israeli Telecommunication
49
Or ElovitchBezeq Israeli Telecommunication
40
Rami NomkinBezeq Israeli Telecommunication
68
Dov KotlerBezeq Israeli Telecommunication
60
Joshua RosensweigBezeq Israeli Telecommunication
63
JeanPierre BizzariCompugen
64
Sanford ZweifachCompugen
60
Ruth ArnonCompugen
86
Yair AharonowitzCompugen
73
Ilan BiranBezeq Israeli Telecommunication
70
Ami BarlevBezeq Israeli Telecommunication
39
Kinneret SavitskyCompugen
50
Zeev VurembrandBezeq Israeli Telecommunication
66
Amnon DickBezeq Israeli Telecommunication
64
Eldad MosheBezeq Israeli Telecommunication
50
Tali SimonBezeq Israeli Telecommunication
48
Haggai HermanBezeq Israeli Telecommunication
51
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. Clal Biotechnology Industries (CBI) is traded on Tel Aviv Stock Exchange in Israel and employs 21 people.

Management Performance

Clal Biotechnology Leadership Team

Elected by the shareholders, the Clal Biotechnology's board of directors comprises two types of representatives: Clal Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clal. The board's role is to monitor Clal Biotechnology's management team and ensure that shareholders' interests are well served. Clal Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clal Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ofer Goldberg, VP
Iris Sadeh, Accountant
Liat Nissan, Controller
Sigalia Heifetz, Director
Shmuel Rubinstein, External Director
Tomer Babai, Director
Dafna Gruber, Director
Aharon Schwartz, Director
Gavriel Barabash, Director
Isaac Kohlberg, Director
Nofar Malovani, Director
Arnon MD, Medical Director
Pr MD, VP MediWound
Assaf Segal, Acting Officer
Ofer Gonen, Vice President
Avraham Fischer, Chairman of the Board
Yuval Yanai, External Director
Julian Adams, President Chief Scientific Officer
Orit Lidor, VP and General Counsel
Shiran Manor, Co Sec
Etty Kliger, VP MediWound

Clal Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clal Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Clal Biotechnology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Clal Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Clal Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Moving together with Clal Stock

  0.64MGDL Migdal InsurancePairCorr
  0.65CLIS Clal Insurance EnterPairCorr
The ability to find closely correlated positions to Clal Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Clal Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Clal Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Clal Biotechnology Industries to buy it.
The correlation of Clal Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Clal Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Clal Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Clal Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clal Biotechnology Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Clal Stock analysis

When running Clal Biotechnology's price analysis, check to measure Clal Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clal Biotechnology is operating at the current time. Most of Clal Biotechnology's value examination focuses on studying past and present price action to predict the probability of Clal Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clal Biotechnology's price. Additionally, you may evaluate how the addition of Clal Biotechnology to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Global Correlations
Find global opportunities by holding instruments from different markets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Please note, there is a significant difference between Clal Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clal Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clal Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.